Lazertinib for NSCLC Harboring Activating EGFR Mutations in TKI naïve Patients

Sponsor
Se-Hoon Lee
Study ID
NCT05463224
Phase
PHASE2
Status
Active Not Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
19 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The primary objective is to evaluate the efficacy/safety of lazertinib and to explore the resistance mechanism of lazertinib as first-line in patients with NSCLC harboring activating EGFR mutations.

Key Dates

Start date
Jan 4, 2023
Status verified
Apr 2026
Primary completion
Dec 1, 2026
Completion
Dec 31, 2027

Study Design

Enrollment
150 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Lazertinib group
    Lazertinib 240mg daily (1 cycle of 21 days)

Primary Outcome Measure

progression-free survival [ Time Frame: through study completion, an average of 18.0 month ]

Related Studies